- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Drug Sales Forecast to Grow Nearly Five Percent Annually, Says Report
June 17, 2015.
Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the US and Europe, fueling a projected five percent increase in global prescription sales over the next five years according to the EvaluatePharma World Preview 2015, Outlook to 2020 report. The 2015 World Preview states that:
- Worldwide prescription drug sales are to reach nearly one trillion dollars by 2020 with a CAGR of 4.8 percent between 2014 and 2020.
- 2014 US prescription drug sales surged 8.9 percent; Europe returned to growth with a 2.4 percent jump while Japanese sales in yen dropped by 2.6 percent.
- R&D pipeline values increased to $492.8 billion from $418.5 billion in 2014; Gilead’s potential new combination hepatitis C product was valued highest at $24.8 billion.
- Humira remained the top-selling product in 2014 with sales of $13.9 billion; Sovaldi debuted at number two with sales of $10 billion.
- FDA approved record-breaking 50 new drugs in 2014 with a 43 percent increase in five-year post-launch sales potential; Bristol-Myers Squibb’s Opdivo was the number one approval.
- Novartis will remain the number one pharmaceutical company through 2020 with total prescription drug sales of $53.3 billion.
- Value of M&A transactions almost doubled to $116 billion in 2014; value of venture financing deals leapt 36 percent to $8.2 billion.
Lisa Urquhart, Editor of EP Vantage, the editorial arm of Evaluate, commented: “Any fears that the pharmaceutical industry might be heading towards a slowdown after the last two years of phenomenal growth can be put to rest for now. However, for the industry to sustain this impressive growth they will have to make compromises around global pricing and market access. As such, pharmaceutical companies need to either accept lower prices for its products, or persuade payers that the therapeutic benefits outweigh the cost of disease.” The EvaluatePharma World Preview 2015, Outlook to 2020 report can be downloaded at
www.evaluategroup.com/WP2015
